Cargando…

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

Agents that target components of the PI3K/AKT/mTOR pathway are under investigation for the treatment of diffuse large B cell lymphoma (DLBCL). Given the highly heterogeneous nature of DLBCL, it is not clear whether all subtypes of DLBCL will be susceptible to PI3K pathway inhibition, or which kinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezell, Scott A., Wang, Suping, Bihani, Teeru, Lai, Zhongwu, Grosskurth, Shaun E., Tepsuporn, Suprawee, Davies, Barry R., Huszar, Dennis, Byth, Kate F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891033/ https://www.ncbi.nlm.nih.gov/pubmed/26824321 http://dx.doi.org/10.18632/oncotarget.7036

Ejemplares similares

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
por: Ezell, Scott A., et al.
Publicado: (2014)

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
por: Bihani, Teeru, et al.
Publicado: (2014)

Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas
por: Rivera-Soto, Ricardo, et al.
Publicado: (2021)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

mTOR activity in AIDS-related diffuse large B-cell lymphoma
por: Browne, Sara H., et al.
Publicado: (2017)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance
por: Majchrzak, Agata, et al.
Publicado: (2014)

Akt and mTOR in B Cell Activation and Differentiation
por: Limon, Jose J., et al.
Publicado: (2012)

Akt and mTOR mediate programmed necrosis in neurons
por: Liu, Q, et al.
Publicado: (2014)

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma
por: Bhatti, Maria, et al.
Publicado: (2018)

ATM-deficient thymic lymphoma is associated with aberrant tcrd rearrangement and gene amplification
por: Zha, Shan, et al.
Publicado: (2010)

mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
por: Xu, Wendan, et al.
Publicado: (2022)

MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
por: Clegg, Nicola J., et al.
Publicado: (2011)

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
por: Wan, Linyan, et al.
Publicado: (2022)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma
por: Mazan-Mamczarz, Krystyna, et al.
Publicado: (2015)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Dynamic Akt/mTOR Signaling in Children with Autism Spectrum Disorder
por: Onore, Charity, et al.
Publicado: (2017)

The Mitochondrial Deubiquitinase USP30 Regulates AKT/mTOR Signaling
por: Zhang, Ruohan, et al.
Publicado: (2022)

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas
por: Argyriou, Pinelopi, et al.
Publicado: (2012)

Aldose reductase interacts with AKT1 to augment hepatic AKT/mTOR signaling and promote hepatocarcinogenesis
por: Zhao, Jia-Xing, et al.
Publicado: (2017)

The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas
por: El Habr, Elias A., et al.
Publicado: (2012)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Essential Roles of mTOR/Akt Pathway in Aurora-A Cell Transformation
por: Taga, Makoto, et al.
Publicado: (2009)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Activation of Akt/mTOR Pathway Is Associated with Poor Prognosis of Nasopharyngeal Carcinoma
por: Wang, Weiyuan, et al.
Publicado: (2014)

Akt1 Enhances CA916798 Expression through mTOR Pathway
por: Wang, Yu-Liang, et al.
Publicado: (2013)

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer
por: Floc'h, Nicolas, et al.
Publicado: (2012)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
por: Xu, Hao, et al.
Publicado: (2018)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2020)

Involvement of Akt/mTOR in the Neurotoxicity of Rotenone-Induced Parkinson’s Disease Models
por: Zhang, Yu, et al.
Publicado: (2019)

Neuroligin 3 Regulates Dendritic Outgrowth by Modulating Akt/mTOR Signaling
por: Xu, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dd3qttk3ih2o1am39b3dmvrkl2